Hubei Jumpcan Pharmaceutical Co (SHSE:600566) LT-Debt-to-Total-Asset : 0.00 (As of Mar. 2024)

View and export this data going back to 2001. Start your Free Trial

What is Hubei Jumpcan Pharmaceutical Co LT-Debt-to-Total-Asset?

LT Debt to Total Assets is a measurement representing the percentage of a corporation's assets that are financed with loans and financial obligations lasting more than one year. The ratio provides a general measure of the financial position of a company, including its ability to meet financial requirements for outstanding loans. It is calculated as a company's Long-Term Debt & Capital Lease Obligationdivide by its Total Assets. Hubei Jumpcan Pharmaceutical Co's long-term debt to total assests ratio for the quarter that ended in Mar. 2024 was 0.00.

Hubei Jumpcan Pharmaceutical Co's long-term debt to total assets ratio stayed the same from Mar. 2023 (0.00) to Mar. 2024 (0.00).

Hubei Jumpcan Pharmaceutical Co LT-Debt-to-Total-Asset Historical Data

The historical data trend for Hubei Jumpcan Pharmaceutical Co's LT-Debt-to-Total-Asset can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Hubei Jumpcan Pharmaceutical Co LT-Debt-to-Total-Asset Chart

Hubei Jumpcan Pharmaceutical Co Annual Data

Trend

Dec14

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

LT-Debt-to-Total-Asset

Get a 7-Day Free Trial

0.07

0.06

Hubei Jumpcan Pharmaceutical Co Quarterly Data
	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24
LT-Debt-to-Total-Asset	Get a 7-Day Free Trial															-	-	-	-	-

Hubei Jumpcan Pharmaceutical Co LT-Debt-to-Total-Asset Calculation

Hubei Jumpcan Pharmaceutical Co's Long-Term Debt to Total Asset Ratio for the fiscal year that ended in Dec. 2023 is calculated as

LT Debt to Total Assets (A: Dec. 2023 )	=	Long-Term Debt & Capital Lease Obligation (A: Dec. 2023 )	/	Total Assets (A: Dec. 2023 )
	=	1.434	/	18143.695
	=	0.00

Hubei Jumpcan Pharmaceutical Co's Long-Term Debt to Total Asset Ratio for the quarter that ended in Mar. 2024 is calculated as

LT Debt to Total Assets (Q: Mar. 2024 )	=	Long-Term Debt & Capital Lease Obligation (Q: Mar. 2024 )	/	Total Assets (Q: Mar. 2024 )
	=	1.133	/	19361.405
	=	0.00

Hubei Jumpcan Pharmaceutical Co (SHSE:600566) LT-Debt-to-Total-Asset Explanation

LT Debt to Total Asset is a measurement representing the percentage of a corporation's assets that are financed with loans and financial obligations lasting more than one year. The ratio provides a general measure of the financial position of a company, including its ability to meet financial requirements for outstanding loans. A year-over-year decrease in this metric would suggest the company is progressively becoming less dependent on debt to grow their business.

Hubei Jumpcan Pharmaceutical Co LT-Debt-to-Total-Asset Related Terms

Thank you for viewing the detailed overview of Hubei Jumpcan Pharmaceutical Co's LT-Debt-to-Total-Asset provided by GuruFocus.com. Please click on the following links to see related term pages.

Hubei Jumpcan Pharmaceutical Co (SHSE:600566) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Hubei Jumpcan Pharmaceutical Co Ltd (SHSE:600566) » Definitions » LT-Debt-to-Total-Asset

Traded in Other Exchanges

N/A

Address

Heights Garden Road, Room 602 fashion, Shashi District, Jingzhou, Hubei, CHN

Website

http://www.jumpcan.com

Hubei Jumpcan Pharmaceutical Co Ltd engages in the research, development, manufacturing, and trading of Chinese traditional medicines, western medicines, daily use chemical based on Chinese traditional medicines, and Chinese medicine health products in China. It offers Chinese and western medicines in the areas of pediatrics, gynecology, pneumology, gastroenterology, and geriatric. The company also develops Chinese and western medicines in the areas of detoxification, digestive system, respiratory system, nervous system, anti-infection, cardiovascular, narcotic analgesic, nutrition, musculoskeletal, and hemostasis.

Executives

Cao Wei	Directors, senior managers
Zhou Qi Hua	senior management
Huang Qu Rong	Director
Yan Hong Quan	senior management
Shi Wen Zheng	senior management
Zhang Jian Min	Director
Cao Long Xiang	Director
Yan Yue Hua	Director

Hubei Jumpcan Pharmaceutical Co (SHSE:600566) Headlines

No Headlines